Loading...
Symbols:
Loading...
Symbols:
Vanda Pharmaceuticals, Inc. (VNDA)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Vanda Pharmaceuticals, Inc. (VNDA)
20 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on VNDA
- Brett Scott(4)
- Centient Biotech Investor(4)
- Andrew Wilkinson(2)
- H.S. Ayoub(2)
- Anthony Payne(2)
Most popular authors
(tracked in watchlists)
- Andrew Wilkinson(334)
- SA Editor Miriam Metzinger(120)
- Notable Calls(112)
- Mike Havrilla(105)
- Derek Lowe(32)
Most commented on authors
- Brett Scott(4)
- Mike Havrilla(4)
- Derek Lowe(2)
- Centient Biotech Investor(1)
- Evelyn Rubin(0)
- 73 Decision Dates on Updated FDA Calendar
- Vanda's Schizophrenia Drug Goes Down for the Last Time
- Monday Options Update: MER, AMGN, SLW, VNDA, PFG, HW
- Thursday's Options Report: MSFT, VNDA, NVTL, XLF, RIMM, GM, ZLC
- 3 Positives From Vanda's Conference Call
- NeurogesX, Vanda Would Do Well To Find Themselves A Partner
- Vanda Pharmaceuticals: Finding Reassurance In Institutional Investors and Fair Value Calculations
- Vanda Pharmaceuticals' Pipeline Nearing FDA Stage
- Vanda Pharmaceuticals Should Jump On Bullish Note
- Potential Acquisitions May Prove Positive For Vanda Pharmaceuticals
- SAC Capital's 2007 Transactions: This Hedge Fund Has Been Busy
- Biotech Stocks: Abbott Sells Lab Division to GE for $8 Billion
- Biotech Rises To New Record High
- Eye on Vanda Pharmaceuticals
- Top Picks for 2007 from JPMorgan HealthCare Analysts
- 2007: The Year Of Biotech IPOs?
- Vanda Schizophrenia Drug Meets Phase III Endpoint
- Vanda's Success Pays For MedImmune Investors
- Vanda Pharmaceuticals' Insomnia Drug Registers Positive Results
- Amicus IPO: A Very Risky Prospect (AMTX)
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »